This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cirillo, I.
Right arrow Articles by Turner, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cirillo, I.
Right arrow Articles by Turner, K.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, October 2008, p. 3478-3483, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00424-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Disposition, Metabolism, and Excretion of [14C]Doripenem after a Single 500-Milligram Intravenous Infusion in Healthy Men{triangledown}

Iolanda Cirillo,1* Geert Mannens,2 Cor Janssen,2 Marc Vermeir,2 Filip Cuyckens,2 Daksha Desai-Krieger,1 Nicole Vaccaro,1 L. Mark Kao,1 Damayanthi Devineni,1 Rebecca Redman,1 and Kenneth Turner1

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Raritan, New Jersey,1 Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V., Beerse, Belgium2

Received 31 March 2008/ Returned for modification 18 May 2008/ Accepted 16 July 2008

In this open-label, single-center study, eight healthy men each received a single 500-mg dose of [14C]doripenem, containing 50 µCi of [14C]doripenem, administered as a 1-h intravenous infusion. The concentrations of unchanged doripenem and its primary metabolite (doripenem-M-1) resulting from β-lactam ring opening were measured in plasma and urine by a validated liquid chromatography method coupled to a tandem mass spectrometry assay. Total radioactivity was measured in blood, plasma, urine, and feces by liquid scintillation counting. Further metabolite profiling was conducted on urine samples using liquid chromatography coupled to radiochemical detection and high-resolution mass spectrometry. Unchanged doripenem and doripenem-M-1 accounted for means of 80.7% and 12.7% of the area under the plasma total-radioactivity-versus-time curve (area under the concentration-time curve extrapolated to infinity) and exhibited elimination half-lives of 1.1 and 2.5 h, respectively. Total clearance of doripenem was 16 liters/h, and renal clearance was 12.5 liters/h. At 7 days after the single dose, 95.3% of total doripenem-related radioactivity was recovered in urine and 0.72% in feces. A total mean of 97.2% of the administered dose was excreted in the urine as unchanged doripenem (78.7% ± 5.7%) and doripenem-M-1 (18.5% ± 2.6%). Most of the urinary recovery occurred within 4 h of dosing. Three additional minor metabolites were identified in urine: the glycine and taurine conjugates of doripenem-M-1 and oxidized doripenem-M-1. These results show that doripenem is predominantly eliminated in urine as unchanged drug, with only a fraction metabolized to doripenem-M-1 and other minor metabolites.

* Corresponding author. Mailing address: Clinical Pharmacology, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., 920 Route 202 South, Raritan, NJ 08869. Phone: (908) 218-6965. Fax: (908) 203-1527. E-mail: icirillo{at}prdus.jnj.com

{triangledown} Published ahead of print on 21 July 2008.

Antimicrobial Agents and Chemotherapy, October 2008, p. 3478-3483, Vol. 52, No. 10
0066-4804/08/$08.00+0     doi:10.1128/AAC.00424-08
Copyright © 2008, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»